The study concluded that SigmaR1 functions as a neuroprotective biomarker of neuronal senescence and pharmacological activation of SigmaR1 could serve as a promising therapeutic strategy for AD [115]. This evidence concerns the gene SIGMAR1 and Alzheimer disease.